↓ Skip to main content

Cochrane Database of Systematic Reviews

Vasopressors for hypotensive shock

Overview of attention for article published in Cochrane database of systematic reviews, February 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

48 X users
12 Facebook pages
4 Wikipedia pages
2 Google+ users


158 Dimensions

Readers on

419 Mendeley
Vasopressors for hypotensive shock
Published in
Cochrane database of systematic reviews, February 2016
DOI 10.1002/14651858.cd003709.pub4
Pubmed ID

Gunnar Gamper, Christof Havel, Jasmin Arrich, Heidrun Losert, Nathan L Pace, Marcus Müllner, Harald Herkner


Initial goal-directed resuscitation for hypotensive shock usually includes administration of intravenous fluids, followed by initiation of vasopressors. Despite obvious immediate effects of vasopressors on haemodynamics, their effect on patient-relevant outcomes remains controversial. This review was published originally in 2004 and was updated in 2011 and again in 2016. Our objective was to compare the effect of one vasopressor regimen (vasopressor alone, or in combination) versus another vasopressor regimen on mortality in critically ill participants with shock. We further aimed to investigate effects on other patient-relevant outcomes and to assess the influence of bias on the robustness of our effect estimates. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015 Issue 6), MEDLINE, EMBASE, PASCAL BioMed, CINAHL, BIOSIS and PsycINFO (from inception to June 2015). We performed the original search in November 2003. We also asked experts in the field and searched meta-registries to identify ongoing trials. Randomized controlled trials (RCTs) comparing various vasopressor regimens for hypotensive shock. Two review authors abstracted data independently. They discussed disagreements between them and resolved differences by consulting with a third review author. We used a random-effects model to combine quantitative data. We identified 28 RCTs (3497 participants) with 1773 mortality outcomes. Six different vasopressors, given alone or in combination, were studied in 12 different comparisons.All 28 studies reported mortality outcomes; 12 studies reported length of stay. Investigators reported other morbidity outcomes in a variable and heterogeneous way. No data were available on quality of life nor on anxiety and depression outcomes. We classified 11 studies as having low risk of bias for the primary outcome of mortality; only four studies fulfilled all trial quality criteria.In summary, researchers reported no differences in total mortality in any comparisons of different vasopressors or combinations in any of the pre-defined analyses (evidence quality ranging from high to very low). More arrhythmias were observed in participants treated with dopamine than in those treated with norepinephrine (high-quality evidence). These findings were consistent among the few large studies and among studies with different levels of within-study bias risk. We found no evidence of substantial differences in total mortality between several vasopressors. Dopamine increases the risk of arrhythmia compared with norepinephrine and might increase mortality. Otherwise, evidence of any other differences between any of the six vasopressors examined is insufficient. We identified low risk of bias and high-quality evidence for the comparison of norepinephrine versus dopamine and moderate to very low-quality evidence for all other comparisons, mainly because single comparisons occasionally were based on only a few participants. Increasing evidence indicates that the treatment goals most often employed are of limited clinical value. Our findings suggest that major changes in clinical practice are not needed, but that selection of vasopressors could be better individualised and could be based on clinical variables reflecting hypoperfusion.

X Demographics

X Demographics

The data shown below were collected from the profiles of 48 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 419 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 <1%
Chile 2 <1%
Netherlands 1 <1%
Colombia 1 <1%
United Kingdom 1 <1%
Norway 1 <1%
Spain 1 <1%
Denmark 1 <1%
Unknown 408 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 63 15%
Student > Bachelor 50 12%
Student > Postgraduate 41 10%
Researcher 36 9%
Other 33 8%
Other 79 19%
Unknown 117 28%
Readers by discipline Count As %
Medicine and Dentistry 198 47%
Nursing and Health Professions 39 9%
Psychology 14 3%
Pharmacology, Toxicology and Pharmaceutical Science 12 3%
Social Sciences 10 2%
Other 22 5%
Unknown 124 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2023.
All research outputs
of 25,387,189 outputs
Outputs from Cochrane database of systematic reviews
of 12,818 outputs
Outputs of similar age
of 413,015 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 235 outputs
Altmetric has tracked 25,387,189 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,818 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 36.3. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 413,015 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 235 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.